Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass
ObjectiveThe aim of this study was to test the hypothesis whether serum level of calpains could become a meaningful biomarker for diagnosis of acute lung injury (ALI) in clinical after cardiac surgery using cardiopulmonary bypass (CPB) technology.Methods and resultsSeventy consecutive adults underwe...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1000761/full |
| _version_ | 1811313340144680960 |
|---|---|
| author | Chenlong Yi Chenlong Yi Fangyu Chen Fangyu Chen Rongrong Ma Zhi Fu Meijuan Song Zhuan Zhang Lingdi Chen Xing Tang Peng Lu Ben Li Qingfen Zhang Qifeng Song Qifeng Song Guangzheng Zhu Guangzheng Zhu Wei Wang Qiang Wang Xiaowei Wang |
| author_facet | Chenlong Yi Chenlong Yi Fangyu Chen Fangyu Chen Rongrong Ma Zhi Fu Meijuan Song Zhuan Zhang Lingdi Chen Xing Tang Peng Lu Ben Li Qingfen Zhang Qifeng Song Qifeng Song Guangzheng Zhu Guangzheng Zhu Wei Wang Qiang Wang Xiaowei Wang |
| author_sort | Chenlong Yi |
| collection | DOAJ |
| description | ObjectiveThe aim of this study was to test the hypothesis whether serum level of calpains could become a meaningful biomarker for diagnosis of acute lung injury (ALI) in clinical after cardiac surgery using cardiopulmonary bypass (CPB) technology.Methods and resultsSeventy consecutive adults underwent cardiac surgery with CPB were included in this prospective study. Based on the American-European Consensus Criteria (AECC), these patients were divided into ALI (n = 20, 28.57%) and non-ALI (n = 50, 71.43%) groups. Serum level of calpains in terms of calpains’ activity which was expressed as relative fluorescence unit (RFU) per microliter and measured at beginning of CPB (baseline), 1 h during CPB, end of CPB as well as 1, 12, and 24 h after CPB. Difference of serum level of calpains between two groups first appeared at the end of CPB and remained different at subsequent test points. Univariate and multivariate logistic regression analysis indicated that serum level of calpains 1 h after CPB was an independent predictor for postoperative ALI (OR 1.011, 95% CI 1.001, 1.021, p = 0.033) and correlated with a lower PaO2/FiO2 ratio in the first 2 days (The first day: r = -0.389, p < 0.001 and the second day: r = -0.320, p = 0.007) as well as longer mechanical ventilation time (r = 0.440, p < 0.001), intensive care unit (ICU) length of stay (LOS) (r = 0.419, p < 0.001) and hospital LOS (r = 0.297, p = 0.013).ConclusionElevated serum level of calpains correlate with impaired lung function and poor clinical outcomes, indicating serum level of calpains could act as a potential biomarker for postoperative ALI following CPB in adults.Clinical trial registration[https://clinicaltrials.gov/show/NCT05610475], identifier [NCT05610475]. |
| first_indexed | 2024-04-13T10:53:17Z |
| format | Article |
| id | doaj.art-4ecbc536d08a476db44213497630487f |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-13T10:53:17Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-4ecbc536d08a476db44213497630487f2022-12-22T02:49:36ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-11-01910.3389/fcvm.2022.10007611000761Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypassChenlong Yi0Chenlong Yi1Fangyu Chen2Fangyu Chen3Rongrong Ma4Zhi Fu5Meijuan Song6Zhuan Zhang7Lingdi Chen8Xing Tang9Peng Lu10Ben Li11Qingfen Zhang12Qifeng Song13Qifeng Song14Guangzheng Zhu15Guangzheng Zhu16Wei Wang17Qiang Wang18Xiaowei Wang19Department of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Thoracic and Cardiovascular Surgery, Dalian Medical University, Dalian, ChinaDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaJiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Anesthesiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Operating Theatre, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Anesthesiology, Peking University People’s Hospital, Beijing, ChinaDepartment of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Thoracic and Cardiovascular Surgery, Dalian Medical University, Dalian, ChinaDepartment of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Thoracic and Cardiovascular Surgery, Dalian Medical University, Dalian, ChinaDepartment of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Cardiovascular Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, ChinaDepartment of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaObjectiveThe aim of this study was to test the hypothesis whether serum level of calpains could become a meaningful biomarker for diagnosis of acute lung injury (ALI) in clinical after cardiac surgery using cardiopulmonary bypass (CPB) technology.Methods and resultsSeventy consecutive adults underwent cardiac surgery with CPB were included in this prospective study. Based on the American-European Consensus Criteria (AECC), these patients were divided into ALI (n = 20, 28.57%) and non-ALI (n = 50, 71.43%) groups. Serum level of calpains in terms of calpains’ activity which was expressed as relative fluorescence unit (RFU) per microliter and measured at beginning of CPB (baseline), 1 h during CPB, end of CPB as well as 1, 12, and 24 h after CPB. Difference of serum level of calpains between two groups first appeared at the end of CPB and remained different at subsequent test points. Univariate and multivariate logistic regression analysis indicated that serum level of calpains 1 h after CPB was an independent predictor for postoperative ALI (OR 1.011, 95% CI 1.001, 1.021, p = 0.033) and correlated with a lower PaO2/FiO2 ratio in the first 2 days (The first day: r = -0.389, p < 0.001 and the second day: r = -0.320, p = 0.007) as well as longer mechanical ventilation time (r = 0.440, p < 0.001), intensive care unit (ICU) length of stay (LOS) (r = 0.419, p < 0.001) and hospital LOS (r = 0.297, p = 0.013).ConclusionElevated serum level of calpains correlate with impaired lung function and poor clinical outcomes, indicating serum level of calpains could act as a potential biomarker for postoperative ALI following CPB in adults.Clinical trial registration[https://clinicaltrials.gov/show/NCT05610475], identifier [NCT05610475].https://www.frontiersin.org/articles/10.3389/fcvm.2022.1000761/fullacute lung injurycalpainscardiopulmonary bypass (CPB)PaO2/FiO2heart surgery |
| spellingShingle | Chenlong Yi Chenlong Yi Fangyu Chen Fangyu Chen Rongrong Ma Zhi Fu Meijuan Song Zhuan Zhang Lingdi Chen Xing Tang Peng Lu Ben Li Qingfen Zhang Qifeng Song Qifeng Song Guangzheng Zhu Guangzheng Zhu Wei Wang Qiang Wang Xiaowei Wang Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass Frontiers in Cardiovascular Medicine acute lung injury calpains cardiopulmonary bypass (CPB) PaO2/FiO2 heart surgery |
| title | Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass |
| title_full | Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass |
| title_fullStr | Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass |
| title_full_unstemmed | Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass |
| title_short | Serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass |
| title_sort | serum level of calpains product as a novel biomarker of acute lung injury following cardiopulmonary bypass |
| topic | acute lung injury calpains cardiopulmonary bypass (CPB) PaO2/FiO2 heart surgery |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1000761/full |
| work_keys_str_mv | AT chenlongyi serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT chenlongyi serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT fangyuchen serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT fangyuchen serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT rongrongma serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT zhifu serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT meijuansong serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT zhuanzhang serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT lingdichen serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT xingtang serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT penglu serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT benli serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT qingfenzhang serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT qifengsong serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT qifengsong serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT guangzhengzhu serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT guangzhengzhu serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT weiwang serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT qiangwang serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass AT xiaoweiwang serumlevelofcalpainsproductasanovelbiomarkerofacutelunginjuryfollowingcardiopulmonarybypass |